Us Vaccine Maker
- All
- News
- Videos
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
US Backs Moderna, Says Government Should Face Covid Vaccine Lawsuit
The USgovernment should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.
-
Covaxin Set To Be Evaluated In US, Says Maker Bharat Biotech
Bharat Biotech on Saturday said its Covaxin will be evaluated as a COVID-19 vaccine candidate in the US.
-
India's Biological E, US Finalise $50 Million Covid Vaccine Deal: Report
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
US To Finance India's Biological E In $50 Million Covid Vaccine Deal
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
Johnson & Johnson Asks US To Authorise Booster Shots Of Covid Vaccine
Drug maker Johnson & Johnson asked the US Food and Drug Administration (FDA) on Tuesday to authorize booster shots of its Covid-19 vaccine for people over the age of 18.
-
Serum Institute Allowed To Enrol 7-11 Year-Olds In Covid Vaccine Trial
The country's drug regulator today allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its trial of US drugmaker Novavax's COVID-19 vaccine.
-
India Covid Latest News LIVE Updates: India Sees Fewest Covid Cases In 75 Days; 2,726 Deaths
Novavax's COVID-19 vaccine is more than 90 per cent effective, including against coronavirus variants, the vaccine maker said Monday after a large-scale US study.
-
Novavax Covid Vaccine, To Be Made By Serum Institute, Shows 90% Efficacy
Novavax's COVID-19 jab is more than 90 percent effective, including against coronavirus variants, the vaccine maker said Monday after a large-scale US study.
-
US Delays Use Of India-Made COVID-19 Vaccine Covaxin. What It Recommended
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data.
-
"Strengthen Pandemic Response": Indian Envoy's Meet With Pfizer CEO In US
Indian Ambassador to the USTaranjit Singh Sandhu on Thursday (local time) met with Pfizer CEO Albert Bouria to discuss ways in which the COVID-19 vaccine maker can support healthcare efforts in India.
-
PM Modi, President Biden Meet At Quad Summit With Japan, Australia
Prime Minister Narendra Modi, US President Joe Biden, Australian Prime Minister Scott Morrison and Japanese Prime Minister Yoshihide Suga came together this evening in a virtual meeting of the leaders of the "Quad" group of nations. The first summit - seen as part of efforts to balance China's growing military and economic power - will focus on a "...
-
Serum's Adar Poonawalla Warns Of Delays As US Prioritizes Pfizer
The head of the world's biggest vaccine maker and the World Health Organization's chief scientist said manufacturers of coronavirus shots face a global shortage of the raw materials needed to churn out the inoculations.
-
US Firm Aims To Make 1 Billion COVID-19 Vaccine Doses After Buying Plant
Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world's largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.
-
Ebola Drug Maker Fujifilm to Buy US Vaccine Maker
Fujifilm said on Monday it would buy a US vaccine maker as the Japanese firm boosts its supply of an experimental Ebola drug to help stem the spread of the virus.
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
US Backs Moderna, Says Government Should Face Covid Vaccine Lawsuit
The USgovernment should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.
-
Covaxin Set To Be Evaluated In US, Says Maker Bharat Biotech
Bharat Biotech on Saturday said its Covaxin will be evaluated as a COVID-19 vaccine candidate in the US.
-
India's Biological E, US Finalise $50 Million Covid Vaccine Deal: Report
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
US To Finance India's Biological E In $50 Million Covid Vaccine Deal
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
Johnson & Johnson Asks US To Authorise Booster Shots Of Covid Vaccine
Drug maker Johnson & Johnson asked the US Food and Drug Administration (FDA) on Tuesday to authorize booster shots of its Covid-19 vaccine for people over the age of 18.
-
Serum Institute Allowed To Enrol 7-11 Year-Olds In Covid Vaccine Trial
The country's drug regulator today allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its trial of US drugmaker Novavax's COVID-19 vaccine.
-
India Covid Latest News LIVE Updates: India Sees Fewest Covid Cases In 75 Days; 2,726 Deaths
Novavax's COVID-19 vaccine is more than 90 per cent effective, including against coronavirus variants, the vaccine maker said Monday after a large-scale US study.
-
Novavax Covid Vaccine, To Be Made By Serum Institute, Shows 90% Efficacy
Novavax's COVID-19 jab is more than 90 percent effective, including against coronavirus variants, the vaccine maker said Monday after a large-scale US study.
-
US Delays Use Of India-Made COVID-19 Vaccine Covaxin. What It Recommended
In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data.
-
"Strengthen Pandemic Response": Indian Envoy's Meet With Pfizer CEO In US
Indian Ambassador to the USTaranjit Singh Sandhu on Thursday (local time) met with Pfizer CEO Albert Bouria to discuss ways in which the COVID-19 vaccine maker can support healthcare efforts in India.
-
PM Modi, President Biden Meet At Quad Summit With Japan, Australia
Prime Minister Narendra Modi, US President Joe Biden, Australian Prime Minister Scott Morrison and Japanese Prime Minister Yoshihide Suga came together this evening in a virtual meeting of the leaders of the "Quad" group of nations. The first summit - seen as part of efforts to balance China's growing military and economic power - will focus on a "...
-
Serum's Adar Poonawalla Warns Of Delays As US Prioritizes Pfizer
The head of the world's biggest vaccine maker and the World Health Organization's chief scientist said manufacturers of coronavirus shots face a global shortage of the raw materials needed to churn out the inoculations.
-
US Firm Aims To Make 1 Billion COVID-19 Vaccine Doses After Buying Plant
Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world's largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.
-
Ebola Drug Maker Fujifilm to Buy US Vaccine Maker
Fujifilm said on Monday it would buy a US vaccine maker as the Japanese firm boosts its supply of an experimental Ebola drug to help stem the spread of the virus.
